Kazumasa Kotake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kazumasa Kotake has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Satoru Mitsuboshi
Department of Pharmacy Kaetsu Hospital Niigata Japan
11 shared publications Yasuhiro Kawakami
Department of Pharmacy, Okayama Saiseikai General Hospital, Okayama-shi, Okayama, Japan
11 shared publicationsMakoto Morizumi
Department of Pharmacy Ohno Memorial Hospital Osaka Japan
5 shared publications- Masahiro Banno
Scientific Research WorkS Peer Support Group (SRWS-PSG)
5 shared publications - Yuki Kataoka
Center for Medical Education, Graduate School of Medicine, Nagoya University
4 shared publications Masuo Tanaka
Department of Psychiatry Zikei Hospital/Zikei Institute of Psychiatry Okayama Japan
3 shared publications
Latest Publications
- 5 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Acute Kidney Injury and Heart Failure Risk with Hypoxia‐Inducible Factor–Prolyl Hydroxylase Inhibitors: A Network Meta‐Analysis
The aim of this systematic review and network meta‐analysis was to clarify the risk of acute kidney injury (AKI) and acute heart failure associated with hypoxia‐inducible factor–prolyl hydroxylase inhibitors (HIF‐PHIs) in patients with anemia of chronic kidney disease. The certainty of evidence for each outcome was assessed using the Confidence in Network Meta‐Analysis approach. The primary outcomes were AKI and acute heart failure, while the secondary outcome was any kidney injury. Thirty‐five studies, performed between 2009 and 2025, were included in the network meta‐analysis. HIF‐PHIs were associated with a higher risk of AKI compared with erythropoiesis‐stimulating agents (ESAs) (risk ratio [RR] 1.23, 95% confidence interval [CI] 1.02–1.47, moderate certainty) and placebo (RR 1.40, 95% CI 1.11–1.75, high certainty). HIF‐PHIs were also associated with an increased risk of any kidney injury compared with placebo (RR 1.13, 95% CI 1.01–1.26, moderate certainty). ESAs ranked lower in terms of acute heart failure risk than both HIF‐PHIs and placebo, although the differences were not statistically significant. Vadadustat (RR 0.30, 95% CI 0.12–0.74, moderate certainty) and ESAs (RR 0.40, 95% CI 0.17–0.94, high certainty) were associated with a lower risk of acute heart failure compared with placebo. In conclusion, HIF‐PHIs may be associated with an increased incidence of AKI compared with placebo and ESAs. In contrast, vadadustat and ESAs might be associated with a decreased incidence of acute heart failure compared with placebo. Further robust studies should be conducted to validate these findings.
- 5 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Acute Kidney Injury and Heart Failure Risk with Hypoxia‐Inducible Factor–Prolyl Hydroxylase Inhibitors: A Network Meta‐Analysis
The aim of this systematic review and network meta‐analysis was to clarify the risk of acute kidney injury (AKI) and acute heart failure associated with hypoxia‐inducible factor–prolyl hydroxylase inhibitors (HIF‐PHIs) in patients with anemia of chronic kidney disease. The certainty of evidence for each outcome was assessed using the Confidence in Network Meta‐Analysis approach. The primary outcomes were AKI and acute heart failure, while the secondary outcome was any kidney injury. Thirty‐five studies, performed between 2009 and 2025, were included in the network meta‐analysis. HIF‐PHIs were associated with a higher risk of AKI compared with erythropoiesis‐stimulating agents (ESAs) (risk ratio [RR] 1.23, 95% confidence interval [CI] 1.02–1.47, moderate certainty) and placebo (RR 1.40, 95% CI 1.11–1.75, high certainty). HIF‐PHIs were also associated with an increased risk of any kidney injury compared with placebo (RR 1.13, 95% CI 1.01–1.26, moderate certainty). ESAs ranked lower in terms of acute heart failure risk than both HIF‐PHIs and placebo, although the differences were not statistically significant. Vadadustat (RR 0.30, 95% CI 0.12–0.74, moderate certainty) and ESAs (RR 0.40, 95% CI 0.17–0.94, high certainty) were associated with a lower risk of acute heart failure compared with placebo. In conclusion, HIF‐PHIs may be associated with an increased incidence of AKI compared with placebo and ESAs. In contrast, vadadustat and ESAs might be associated with a decreased incidence of acute heart failure compared with placebo. Further robust studies should be conducted to validate these findings.
- Open Access
- 22 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1)
Association between dispensing regulations for extended-release methylphenidate and prescription trends in Japan: an exploratory descriptive study
Background: In December 2019, a nationwide registration system with strict distribution controls for extended-release methylphenidate (ER-MPH) was introduced to prevent inappropriate use while maintaining treatment access for patients with attention deficit hyperactivity disorder (ADHD). However, its impact on prescription patterns remains unclear. Methods: We conducted an observational study using Japan’s National Database of Health Insurance Claims from 2016 to 2022. ER-MPH prescription volumes were calculated as defined daily doses per 1,000 individuals. Interrupted time series (ITS) analysis was performed to assess the impact of the 2019 distribution-control policy across age and sex groups. We additionally examined whether regional differences in prescription trends could be explained by access to care by assessing the correlation between ER-MPH prescription volumes and the distribution of board-certified pediatricians using Pearson’s correlation coefficients. Results: ER-MPH prescriptions continued to increase after the 2019 policy implementation, but ITS analysis revealed a substantial slowdown in the growth rate. Prescriptions declined immediately by 7% at policy implementation ( level change incidence rate ratio [IRR] = 0.93, 95% confidence interval [CI]: 0.89–0.96), and the annual growth rate slowed from 27% pre-policy (IRR = 1.27, 95% CI: 1.25–1.28) to 9% post-policy (IRR = 1.09, 95% CI: 1.08–1.10) (slope change IRR = 0.86, 95% CI: 0.85–0.87). Age-stratified analyses revealed differential impacts: individuals aged < 20 years showed a 47% immediate decline (IRR = 0.53, 95% CI: 0.42–0.68) with nearly flat subsequent growth, while adults aged ≥ 20 years had only a 19% reduction (IRR = 0.81, 95% CI: 0.79–0.84) and continued slower growth. Sex-specific analyses also showed attenuated growth. The correlation between prescription volumes and pediatrician distribution was weak, indicating no substantial relationship. Conclusions: The 2019 distribution-control measures markedly attenuated the existing upward trend, especially among individuals aged < 20 years. Although prescription patterns differed by age and sex, these differences alone did not fully explain the overall attenuation, and regional variation showed only weak correlations with pediatrician distribution. These findings suggest that additional factors such as psychiatrist availability and broader healthcare system characteristics may also have influenced prescribing trends, underscoring the need for further investigation.
- 22 December 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1)
Open AccessAssociation between dispensing regulations for extended-release methylphenidate and prescription trends in Japan: an exploratory descriptive study
Background: In December 2019, a nationwide registration system with strict distribution controls for extended-release methylphenidate (ER-MPH) was introduced to prevent inappropriate use while maintaining treatment access for patients with attention deficit hyperactivity disorder (ADHD). However, its impact on prescription patterns remains unclear. Methods: We conducted an observational study using Japan’s National Database of Health Insurance Claims from 2016 to 2022. ER-MPH prescription volumes were calculated as defined daily doses per 1,000 individuals. Interrupted time series (ITS) analysis was performed to assess the impact of the 2019 distribution-control policy across age and sex groups. We additionally examined whether regional differences in prescription trends could be explained by access to care by assessing the correlation between ER-MPH prescription volumes and the distribution of board-certified pediatricians using Pearson’s correlation coefficients. Results: ER-MPH prescriptions continued to increase after the 2019 policy implementation, but ITS analysis revealed a substantial slowdown in the growth rate. Prescriptions declined immediately by 7% at policy implementation ( level change incidence rate ratio [IRR] = 0.93, 95% confidence interval [CI]: 0.89–0.96), and the annual growth rate slowed from 27% pre-policy (IRR = 1.27, 95% CI: 1.25–1.28) to 9% post-policy (IRR = 1.09, 95% CI: 1.08–1.10) (slope change IRR = 0.86, 95% CI: 0.85–0.87). Age-stratified analyses revealed differential impacts: individuals aged < 20 years showed a 47% immediate decline (IRR = 0.53, 95% CI: 0.42–0.68) with nearly flat subsequent growth, while adults aged ≥ 20 years had only a 19% reduction (IRR = 0.81, 95% CI: 0.79–0.84) and continued slower growth. Sex-specific analyses also showed attenuated growth. The correlation between prescription volumes and pediatrician distribution was weak, indicating no substantial relationship. Conclusions: The 2019 distribution-control measures markedly attenuated the existing upward trend, especially among individuals aged < 20 years. Although prescription patterns differed by age and sex, these differences alone did not fully explain the overall attenuation, and regional variation showed only weak correlations with pediatrician distribution. These findings suggest that additional factors such as psychiatrist availability and broader healthcare system characteristics may also have influenced prescribing trends, underscoring the need for further investigation.
- 2 October 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3315-3322
Association between use of lubiprostone and headache: A systematic review and meta‐analysis of randomized controlled trials
Aims: Lubiprostone and its active metabolite may activate prostaglandin receptors, raising concerns about an increased risk of headache. We performed a systematic review and meta‐analysis to identify whether lubiprostone increases the risk of headache. Methods: To identify all relevant randomized controlled trials (RCTs), we comprehensively searched MEDLINE (via PubMed), ClinicalTrials.gov website and the Cochrane Central Register of Controlled Trials. The search focused on studies comparing lubiprostone vs . placebo or other laxatives. A DerSimonian–Laird random‐effects model was utilized to estimate risk ratios (RRs) and 95% confidence intervals (CIs). A fixed‐effect method based on the Mantel–Haenszel method was employed for analyses with 3 or fewer studies. Heterogeneity was assessed using the I 2 statistic, and the certainty of evidence was rated using the GRADE approach. Results: Twenty‐six studies were examined in the analysis. The incidence of headache was 5.3% for lubiprostone and 3.2% for placebo or other laxatives. Lubiprostone increased the risk of headache (RR 1.32, 95% CI 1.02–1.71, I 2 = 0%, 6265 patients, 26 RCTs, moderate certainty) relative to placebo or other laxatives. The risk of headache seemed to be consistently increased in both adults (RR 1.23, 95% CI 0.93–1.62, I 2 = 0%, 5390 patients, 24 RCTs, moderate certainty) and children (RR 3.07, 95% CI 1.67–5.63, I 2 = 84.4%, 875 patients, 2 RCTs, very low certainty). Conclusion: The results of this meta‐analysis suggest that lubiprostone treatment increases the risk of headache in adults.
- 2 October 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3315-3322
Association between use of lubiprostone and headache: A systematic review and meta‐analysis of randomized controlled trials
Aims: Lubiprostone and its active metabolite may activate prostaglandin receptors, raising concerns about an increased risk of headache. We performed a systematic review and meta‐analysis to identify whether lubiprostone increases the risk of headache. Methods: To identify all relevant randomized controlled trials (RCTs), we comprehensively searched MEDLINE (via PubMed), ClinicalTrials.gov website and the Cochrane Central Register of Controlled Trials. The search focused on studies comparing lubiprostone vs . placebo or other laxatives. A DerSimonian–Laird random‐effects model was utilized to estimate risk ratios (RRs) and 95% confidence intervals (CIs). A fixed‐effect method based on the Mantel–Haenszel method was employed for analyses with 3 or fewer studies. Heterogeneity was assessed using the I 2 statistic, and the certainty of evidence was rated using the GRADE approach. Results: Twenty‐six studies were examined in the analysis. The incidence of headache was 5.3% for lubiprostone and 3.2% for placebo or other laxatives. Lubiprostone increased the risk of headache (RR 1.32, 95% CI 1.02–1.71, I 2 = 0%, 6265 patients, 26 RCTs, moderate certainty) relative to placebo or other laxatives. The risk of headache seemed to be consistently increased in both adults (RR 1.23, 95% CI 0.93–1.62, I 2 = 0%, 5390 patients, 24 RCTs, moderate certainty) and children (RR 3.07, 95% CI 1.67–5.63, I 2 = 84.4%, 875 patients, 2 RCTs, very low certainty). Conclusion: The results of this meta‐analysis suggest that lubiprostone treatment increases the risk of headache in adults.
- Open Access
- 29 June 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 4 (3) , e70136
Comparative efficacy and safety of intravenous racemic ketamine, repetitive transcranial magnetic stimulation and electroconvulsive therapy for Stage 2 or higher treatment‐resistant depression: A systematic review and network meta‐analysis
Although electroconvulsive therapy (ECT) is the standard treatment for Stage 2 or higher treatment‐resistant depression, it has several drawbacks. Repetitive transcranial magnetic stimulation (rTMS) and intravenous racemic ketamine (IV ketamine) have emerged as potential alternatives, but their comparative effectiveness and safety remain unclear due to limited evidence. We systematically searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and trial registries for randomized controlled trials (RCTs) up to 18 December 2023. Random‐effects network meta‐analyses were performed to compare the antidepressant efficacy, tolerability, and acceptability of ECT, IV ketamine, and rTMS. Thirty‐five RCTs (n = 2109) were included. Most of the included studies had small sample sizes. There were no significant differences in response rate, remission rate, or tolerability of IV ketamine, rTMS, and ECT, while IV ketamine had significantly higher acceptability compared to rTMS and ECT. The confidence in the evidence for efficacy, tolerability, and acceptability was very low. IV ketamine and rTMS did not demonstrate apparent inferiority to ECT in terms of antidepressant efficacy and safety. Considering the various drawbacks of ECT, both treatments may have the potential to serve as viable alternatives. However, the confidence of the evidence in this study is rated as very low, possibly due to small‐study bias, highlighting the need for further large‐scale studies to strengthen the findings.
- 29 June 2025
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 4 (3) , e70136
Open AccessComparative efficacy and safety of intravenous racemic ketamine, repetitive transcranial magnetic stimulation and electroconvulsive therapy for Stage 2 or higher treatment‐resistant depression: A systematic review and network meta‐analysis
Although electroconvulsive therapy (ECT) is the standard treatment for Stage 2 or higher treatment‐resistant depression, it has several drawbacks. Repetitive transcranial magnetic stimulation (rTMS) and intravenous racemic ketamine (IV ketamine) have emerged as potential alternatives, but their comparative effectiveness and safety remain unclear due to limited evidence. We systematically searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and trial registries for randomized controlled trials (RCTs) up to 18 December 2023. Random‐effects network meta‐analyses were performed to compare the antidepressant efficacy, tolerability, and acceptability of ECT, IV ketamine, and rTMS. Thirty‐five RCTs (n = 2109) were included. Most of the included studies had small sample sizes. There were no significant differences in response rate, remission rate, or tolerability of IV ketamine, rTMS, and ECT, while IV ketamine had significantly higher acceptability compared to rTMS and ECT. The confidence in the evidence for efficacy, tolerability, and acceptability was very low. IV ketamine and rTMS did not demonstrate apparent inferiority to ECT in terms of antidepressant efficacy and safety. Considering the various drawbacks of ECT, both treatments may have the potential to serve as viable alternatives. However, the confidence of the evidence in this study is rated as very low, possibly due to small‐study bias, highlighting the need for further large‐scale studies to strengthen the findings.
- 16 June 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (8) , 701-706
Analysis of Esophageal Ulcers Using the Japanese Adverse Drug Event Report Database
Goals: Identifying oral and parenteral drugs associated with esophageal ulcers is important. A comprehensive analysis of a spontaneous adverse event reporting database can support early detection and prevention of drug-induced esophageal ulcers. Background: Drug-induced esophageal ulcers are primarily associated with orally administered drugs. However, recent studies have suggested potential association with parenterally administered drugs. These parenteral cases have not been comprehensively analyzed in previous research. Study: We conducted disproportionality analysis using data from the Japanese Adverse Drug Event Report (JADER) database between April 2004 and December 2023. Signals for esophageal ulcers were detected using the reporting odds ratio with a 95% confidence interval. Weibull distribution analysis was performed to determine the time to adverse event onset for drugs showing signals of esophageal ulcers. Orally and parenterally administered drugs were analyzed separately. Results: Signals were detected for 15 orally administered drugs and 7 parenterally administered anticancer drugs. Weibull distribution analysis revealed that doxycycline and dabigatran etexilate induced the early onset of pill-induced esophagitis, with median onset times of 8 and 12.5 days. Meanwhile, bevacizumab and paclitaxel showed consistent occurrence patterns of esophageal ulcers throughout the treatment period. Conclusions: Our comprehensive analysis of the JADER database identified signals for esophageal ulcers associated with both oral and parenteral drugs, along with their characteristic onset patterns. These findings highlight the clinical importance of considering the potential for esophageal ulcers with specific oral and parenteral drugs and suggest that early intervention may be crucial in mitigating their occurrence.
- 16 June 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (8) , 701-706
Analysis of Esophageal Ulcers Using the Japanese Adverse Drug Event Report Database
Goals: Identifying oral and parenteral drugs associated with esophageal ulcers is important. A comprehensive analysis of a spontaneous adverse event reporting database can support early detection and prevention of drug-induced esophageal ulcers. Background: Drug-induced esophageal ulcers are primarily associated with orally administered drugs. However, recent studies have suggested potential association with parenterally administered drugs. These parenteral cases have not been comprehensively analyzed in previous research. Study: We conducted disproportionality analysis using data from the Japanese Adverse Drug Event Report (JADER) database between April 2004 and December 2023. Signals for esophageal ulcers were detected using the reporting odds ratio with a 95% confidence interval. Weibull distribution analysis was performed to determine the time to adverse event onset for drugs showing signals of esophageal ulcers. Orally and parenterally administered drugs were analyzed separately. Results: Signals were detected for 15 orally administered drugs and 7 parenterally administered anticancer drugs. Weibull distribution analysis revealed that doxycycline and dabigatran etexilate induced the early onset of pill-induced esophagitis, with median onset times of 8 and 12.5 days. Meanwhile, bevacizumab and paclitaxel showed consistent occurrence patterns of esophageal ulcers throughout the treatment period. Conclusions: Our comprehensive analysis of the JADER database identified signals for esophageal ulcers associated with both oral and parenteral drugs, along with their characteristic onset patterns. These findings highlight the clinical importance of considering the potential for esophageal ulcers with specific oral and parenteral drugs and suggest that early intervention may be crucial in mitigating their occurrence.
- Open Access
- 20 May 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 1-8
GRIK1 genotype and effect of topiramate for alcohol use: a systematic review
Background: Topiramate has shown efficacy in reducing alcohol consumption and is increasingly used off-label for individuals with harmful alcohol use. However, findings regarding the moderating effect of the GRIK1 rs2832407 single nucleotide polymorphism (SNP) on treatment outcomes remain inconsistent, highlighting the need for a review of the current evidence. We evaluated whether the GRIK1 rs2832407 SNP moderates the efficacy and safety of topiramate treatment for alcohol use. Methods: We searched multiple databases including MEDLINE, Cochrane Library, ClinicalTrials.gov, and the International Clinical Trials Registry Platform up to December 1, 2024. Randomized controlled trials (RCTs) comparing treatment outcomes of topiramate in patients with alcohol use who were homozygous for the C allele at rs2832407 with those carrying one or more A alleles at rs2832407 were included. Primary outcomes were heavy drinking days (HDDs) and percentage of days abstinent (PDA), and the secondary outcome was side effects. Each outcome was evaluated using version 2 of the Cochrane Risk of Bias tool. Results: Our analysis included four RCTs. Among three studies evaluating HDDs, only one study demonstrated genotype effects, demonstrating a reduction in HDDs among CC carriers. Of two studies examining PDA, only one revealed genotype effects, indicating an increase in PDA. Side effects were evaluated in two studies, both of which assessed the severity of side effects, but with conflicting results regarding the effect of genotype. Conclusions: This systematic review highlights the current lack of sufficient evidence to confirm the pharmacogenetic effect of the GRIK1 rs2832407 SNP on the efficacy or safety of topiramate treatment in individuals with harmful alcohol use. Trial registration: This research was prospectively registered with the Open Science Framework (https://osf.io/z2awu/).
- 20 May 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 1-8
Open AccessGRIK1 genotype and effect of topiramate for alcohol use: a systematic review
Background: Topiramate has shown efficacy in reducing alcohol consumption and is increasingly used off-label for individuals with harmful alcohol use. However, findings regarding the moderating effect of the GRIK1 rs2832407 single nucleotide polymorphism (SNP) on treatment outcomes remain inconsistent, highlighting the need for a review of the current evidence. We evaluated whether the GRIK1 rs2832407 SNP moderates the efficacy and safety of topiramate treatment for alcohol use. Methods: We searched multiple databases including MEDLINE, Cochrane Library, ClinicalTrials.gov, and the International Clinical Trials Registry Platform up to December 1, 2024. Randomized controlled trials (RCTs) comparing treatment outcomes of topiramate in patients with alcohol use who were homozygous for the C allele at rs2832407 with those carrying one or more A alleles at rs2832407 were included. Primary outcomes were heavy drinking days (HDDs) and percentage of days abstinent (PDA), and the secondary outcome was side effects. Each outcome was evaluated using version 2 of the Cochrane Risk of Bias tool. Results: Our analysis included four RCTs. Among three studies evaluating HDDs, only one study demonstrated genotype effects, demonstrating a reduction in HDDs among CC carriers. Of two studies examining PDA, only one revealed genotype effects, indicating an increase in PDA. Side effects were evaluated in two studies, both of which assessed the severity of side effects, but with conflicting results regarding the effect of genotype. Conclusions: This systematic review highlights the current lack of sufficient evidence to confirm the pharmacogenetic effect of the GRIK1 rs2832407 SNP on the efficacy or safety of topiramate treatment in individuals with harmful alcohol use. Trial registration: This research was prospectively registered with the Open Science Framework (https://osf.io/z2awu/).
- 10 May 2025
- Published by Springer Nature in CNS Drugs
- p. 1-17
Optimal Dose of Baclofen for the Treatment of Alcohol Use Disorder: A Systematic Review and Dose-Response Meta-analysis
Background and Objectives Baclofen, a traditional treatment for spasticity, is gaining interest for its use in alcohol use disorder (AUD). To assist clinicians in using baclofen for effective and safe treatment of AUD, we investigated the optimal target dosage of baclofen through a systematic review and dose-response meta-analysis. Methods We searched Cochrane, EMBASE, MEDLINE via PubMed, PsycINFO, ClinicalTrials.gov, and the International Clinical Trials Registry Platform for randomized controlled trials on 1 and 2 April 2024. Inclusion criteria were patients aged ≥ 18 years diagnosed with AUD according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV, DSM-IV-TR, or International Classification of Diseases (ICD)-10, and treated with baclofen monotherapy. Continuous outcomes—percent days abstinent, drinks per drinking day, heavy drinking days (HDDs), craving, and anxiety—were analyzed as mean or standardized mean differences. Binary outcomes—relapse and dropout, including due to adverse events—were analyzed as odds ratios. Each outcome was assessed using the Cochrane Risk of Bias 2.0 tool. A one-stage random-effects dose-response meta-analysis was performed using restricted cubic splines with fixed knots at 10%, 50%, and 90% percentiles. Results A total of 14 trials (1344 patients) were included. Increasing the dose of baclofen up to 50–60 mg/day was associated with a higher percent days abstinent and reduced craving. However, a higher baclofen dose increases the risk of dropout due to adverse events. Commonly observed adverse events were drowsiness, sedation, somnolence and fatigue. Baclofen up to 50–60 mg/day did not significantly affect drinks per drinking day, HDDs, anxiety, relapse or dropout. Doses > 60 mg/day lacked reliable evaluation due to limited data and study heterogeneity. Conclusions Baclofen up to 50–60 mg/day may increase percent days abstinent and reduce craving, but may increase dropout due to adverse events. Clinicians should carefully consider individual patient factors when prescribing baclofen to patients with AUD.
- 10 May 2025
- Published by Springer Nature in CNS Drugs
- p. 1-17
Optimal Dose of Baclofen for the Treatment of Alcohol Use Disorder: A Systematic Review and Dose-Response Meta-analysis
Background and Objectives Baclofen, a traditional treatment for spasticity, is gaining interest for its use in alcohol use disorder (AUD). To assist clinicians in using baclofen for effective and safe treatment of AUD, we investigated the optimal target dosage of baclofen through a systematic review and dose-response meta-analysis. Methods We searched Cochrane, EMBASE, MEDLINE via PubMed, PsycINFO, ClinicalTrials.gov, and the International Clinical Trials Registry Platform for randomized controlled trials on 1 and 2 April 2024. Inclusion criteria were patients aged ≥ 18 years diagnosed with AUD according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV, DSM-IV-TR, or International Classification of Diseases (ICD)-10, and treated with baclofen monotherapy. Continuous outcomes—percent days abstinent, drinks per drinking day, heavy drinking days (HDDs), craving, and anxiety—were analyzed as mean or standardized mean differences. Binary outcomes—relapse and dropout, including due to adverse events—were analyzed as odds ratios. Each outcome was assessed using the Cochrane Risk of Bias 2.0 tool. A one-stage random-effects dose-response meta-analysis was performed using restricted cubic splines with fixed knots at 10%, 50%, and 90% percentiles. Results A total of 14 trials (1344 patients) were included. Increasing the dose of baclofen up to 50–60 mg/day was associated with a higher percent days abstinent and reduced craving. However, a higher baclofen dose increases the risk of dropout due to adverse events. Commonly observed adverse events were drowsiness, sedation, somnolence and fatigue. Baclofen up to 50–60 mg/day did not significantly affect drinks per drinking day, HDDs, anxiety, relapse or dropout. Doses > 60 mg/day lacked reliable evaluation due to limited data and study heterogeneity. Conclusions Baclofen up to 50–60 mg/day may increase percent days abstinent and reduce craving, but may increase dropout due to adverse events. Clinicians should carefully consider individual patient factors when prescribing baclofen to patients with AUD.
- 22 November 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (1) , 43-53
Association between mineralocorticoid receptor antagonists and kidney harm: A systematic review and meta‐analysis of randomized controlled trials
Conflicting data have been reported on the association between mineralocorticoid receptor antagonists (MRAs) and acute kidney injury (AKI). This systematic review and meta‐analysis aimed to evaluate whether MRAs affect the risk of AKI. MEDLINE via PubMed, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov website were comprehensively searched to extract all relevant studies. Randomized controlled trials (RCTs) were selected that compared MRA versus placebo or no treatment and had study populations consisting of patients with heart or kidney disease. The primary outcome was AKI. The secondary outcome was kidney injury, including AKI and non‐AKI. Thirty‐three studies were included in the meta‐analysis. MRAs were not associated with an increased risk of AKI (risk ratio [RR] 1.13, 95% confidence interval [CI] 0.88–1.46, p = 0.29, I2 = 15%, 18,065 patients, 13 RCTs, moderate certainty). For the secondary outcome, MRAs were associated with an increased risk of kidney injury (RR 1.52, 95% CI 1.24–1.87, p < 0.01, I2 = 48%, 27,492 patients, 33 RCTs, low certainty). In particular, only canrenone (RR 5.39, 95% CI 2.17–13.37, p < 0.01) and spironolactone (RR 1.78, 95% CI 1.48–2.14, p < 0.01) were associated with an increased risk of kidney injury. However, eplerenone and finerenone seem not to increase the risk of kidney injury in patients with heart or kidney disease. The selection of MRAs might influence the risk of kidney‐associated events. Further studies focusing on individual MRAs may be needed to clarify these differences.
- 22 November 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (1) , 43-53
Association between mineralocorticoid receptor antagonists and kidney harm: A systematic review and meta‐analysis of randomized controlled trials
Conflicting data have been reported on the association between mineralocorticoid receptor antagonists (MRAs) and acute kidney injury (AKI). This systematic review and meta‐analysis aimed to evaluate whether MRAs affect the risk of AKI. MEDLINE via PubMed, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov website were comprehensively searched to extract all relevant studies. Randomized controlled trials (RCTs) were selected that compared MRA versus placebo or no treatment and had study populations consisting of patients with heart or kidney disease. The primary outcome was AKI. The secondary outcome was kidney injury, including AKI and non‐AKI. Thirty‐three studies were included in the meta‐analysis. MRAs were not associated with an increased risk of AKI (risk ratio [RR] 1.13, 95% confidence interval [CI] 0.88–1.46, p = 0.29, I2 = 15%, 18,065 patients, 13 RCTs, moderate certainty). For the secondary outcome, MRAs were associated with an increased risk of kidney injury (RR 1.52, 95% CI 1.24–1.87, p < 0.01, I2 = 48%, 27,492 patients, 33 RCTs, low certainty). In particular, only canrenone (RR 5.39, 95% CI 2.17–13.37, p < 0.01) and spironolactone (RR 1.78, 95% CI 1.48–2.14, p < 0.01) were associated with an increased risk of kidney injury. However, eplerenone and finerenone seem not to increase the risk of kidney injury in patients with heart or kidney disease. The selection of MRAs might influence the risk of kidney‐associated events. Further studies focusing on individual MRAs may be needed to clarify these differences.
- Open Access
- 22 October 2024
- Published by Wiley
Analysis of esophageal ulcers using the Japanese Adverse Drug Event Report database
Aim: Drug-induced esophageal ulcers are primarily associated with orally administered drugs, although recent studies have suggested an association with parenterally administered drugs, particularly immune checkpoint inhibitors. However, such cases have not been comprehensively analyzed. Identifying potential associations between various drugs and esophageal ulcers using spontaneous adverse event reporting database is beneficial in reducing drug-induced esophageal ulcers. Methods: We conducted a disproportionality analysis using data from the Japanese Adverse Drug Event Report (JADER) database data from April, 2004 to December, 2023. Signals for esophageal ulcers were detected using the reporting odds ratio with a 95% confidence interval. Weibull distribution analysis was performed to determine the time to adverse event onset for drugs showing signals for esophageal ulcers. We analyzed both orally and parenterally administered drugs separately. Results: Signals for esophageal ulcers were detected with 15 orally administered drugs and seven parenterally administered anticancer drugs, including an immune checkpoint inhibitor (pembrolizumab). Weibull distribution analysis revealed that doxycycline and dabigatran etexilate induced the early onset of esophageal ulcers with median onset times of 8 and 12.5 days, respectively. Conclusion: Our comprehensive investigation using the JADER database revealed that the onset of esophageal ulcers was associated not only for orally administered drugs but also for parenteral administered anticancer drugs, including pembrolizumab. Specifically, doxycycline and dabigatran etexilate may induce the early onset of esophageal ulcers. Overall, our findings highlight the need for early interventions with signal-detecting drugs to prevent and manage esophageal ulcers.
- 22 October 2024
- Published by Wiley
Open AccessAnalysis of esophageal ulcers using the Japanese Adverse Drug Event Report database
Aim: Drug-induced esophageal ulcers are primarily associated with orally administered drugs, although recent studies have suggested an association with parenterally administered drugs, particularly immune checkpoint inhibitors. However, such cases have not been comprehensively analyzed. Identifying potential associations between various drugs and esophageal ulcers using spontaneous adverse event reporting database is beneficial in reducing drug-induced esophageal ulcers. Methods: We conducted a disproportionality analysis using data from the Japanese Adverse Drug Event Report (JADER) database data from April, 2004 to December, 2023. Signals for esophageal ulcers were detected using the reporting odds ratio with a 95% confidence interval. Weibull distribution analysis was performed to determine the time to adverse event onset for drugs showing signals for esophageal ulcers. We analyzed both orally and parenterally administered drugs separately. Results: Signals for esophageal ulcers were detected with 15 orally administered drugs and seven parenterally administered anticancer drugs, including an immune checkpoint inhibitor (pembrolizumab). Weibull distribution analysis revealed that doxycycline and dabigatran etexilate induced the early onset of esophageal ulcers with median onset times of 8 and 12.5 days, respectively. Conclusion: Our comprehensive investigation using the JADER database revealed that the onset of esophageal ulcers was associated not only for orally administered drugs but also for parenteral administered anticancer drugs, including pembrolizumab. Specifically, doxycycline and dabigatran etexilate may induce the early onset of esophageal ulcers. Overall, our findings highlight the need for early interventions with signal-detecting drugs to prevent and manage esophageal ulcers.